Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

US stocks trimmed early session gains on Monday morning, as investors focused on tech's significant — if temporary — reprieve ...

Former speed skater Sarah Lindsay, 44, believes injections like Ozempic and Mounjaro are causing users to be malnourished and ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

It seems like everyone and their sister is taking a GLP-1 (“glucagon-like peptide-1 receptor agonists,” if you’re feeling ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had ...